NASDAQ:TXMD

TherapeuticsMD Q2 2025 Earnings Results & Report

TherapeuticsMD logo
$1.71 -0.10 (-5.52%)
As of 11/20/2026 04:00 PM Eastern

TherapeuticsMD reported Q2 2025 earnings on August 12, 2025. The company reported EPS of $0.05, while revenue was $950 thousand.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
After Market Closes
Conference Call
12:00 AM ET

TherapeuticsMD EPS Results

Actual EPS
$0.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 5 quarters

TherapeuticsMD Revenue Results

Actual Revenue
$950 thousand
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TherapeuticsMD Q2 2025 Earnings FAQ

TherapeuticsMD (NASDAQ:TXMD) reported earnings of $0.05 per share for Q2 2025. The report was announced on Tuesday, August 12, 2025.

TherapeuticsMD reported revenue of $950 thousand for Q2 2025.

TherapeuticsMD Earnings Headlines

Your $7 scanner is waiting
The Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which stock, what price, and when to exit. The list reads the same whether you've traded for twenty years or twenty days, and it doesn't depend on account size. If it's not for you, refund the $7 and still keep the scanner for the full year. One payment, no re-bills.tc pixel
See More TherapeuticsMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TherapeuticsMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TherapeuticsMD and other key companies, straight to your email.

About TherapeuticsMD

TherapeuticsMD (NASDAQ:TXMD) was a U.S. women’s health pharmaceutical company that developed and commercialized prescription products addressing contraception and symptoms associated with menopause. Its business was primarily focused on the U.S. market.

The company’s products included ANNOVERA, a reusable contraceptive vaginal system; IMVEXXY, estradiol vaginal inserts prescribed for certain menopausal symptoms; and BIJUVA, an oral estradiol and progesterone treatment for moderate-to-severe vasomotor symptoms associated with menopause in eligible women.

In 2023, TherapeuticsMD sold substantially all of its assets, including rights to these products, to Mayne Pharma. The products and commercial activities described here reflect TherapeuticsMD’s historical business.

View TherapeuticsMD Profile